{"id":94898,"date":"2026-01-30T04:08:33","date_gmt":"2026-01-30T04:08:33","guid":{"rendered":"https:\/\/www.europesays.com\/lt\/94898\/"},"modified":"2026-01-30T04:08:33","modified_gmt":"2026-01-30T04:08:33","slug":"lietuviu-imone-pasirinkta-vakcinos-nuo-nipos-viruso-gamybai","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/lt\/94898\/","title":{"rendered":"Lietuvi\u0173 \u012fmon\u0117 pasirinkta vakcinos nuo Nipos viruso gamybai"},"content":{"rendered":"

Prane\u0161ime \u017einiasklaidai ra\u0161oma, kad \u201eExpreS2ion\u201c pasirinko \u201eNorthway Biotech\u201c kaip gamybos partner\u012f \u012fvertinusi s\u0117kming\u0105 ankstesnio bendradarbiavimo patirt\u012f ir \u012fmon\u0117s kompetencij\u0105 dirbant su specifine \u201eExpreS2\u201c rekombinantini\u0173 baltym\u0173 platforma. <\/p>\n

Atsakas \u012f augan\u010di\u0105 sveikatos gr\u0117sm\u0119<\/p>\n

\u0160i vakcinos gamybos programa yra dalis \u201eExpreS2ion\u201c \u012fgyvendinamo ir Europos S\u0105jungos programos \u201eEuropos horizontas\u201c l\u0117\u0161omis finansuojamo projekto \u201eVICI-Disease\u201c. <\/p>\n

Poreikis operatyviai vystyti vakcin\u0105 tapo itin aktualus Indijoje v\u0117l u\u017efiksavus pavojingo Nipos (Nipah) viruso (NiV) protr\u016bkius. D\u0117l didelio mirtingumo ir specifini\u0173 gydymo priemoni\u0173 tr\u016bkumo \u0161is patogenas laikomas vienu did\u017eiausi\u0173 tarptautini\u0173 sveikatos prioritet\u0173.<\/p>\n

Nipah virusas pasi\u017eymi itin dideliu mirtingumu, siekian\u010diu nuo 40 iki 75 proc., o patvirtint\u0173 vakcin\u0173 \u0161iuo metu n\u0117ra. Virusas sukelia sunkius kv\u0117pavimo tak\u0173 susirgimus bei mirtin\u0105 encefalit\u0105, tod\u0117l jo suvaldymas yra esminis globalaus saugumo u\u017edavinys.<\/p>\n

Nuo technologij\u0173 vystymo iki produkto klinikiniams tyrimams <\/p>\n

\u201eNorthway Biotech\u201c laboratorijose Vilniuje bus vykdomas vakcinos<\/a> gamybos proces\u0173 vystymas bei geros gamybos praktikos standartus atitinkan\u010dios vaistin\u0117s substancijos ir vaistinio produkto gamyba. <\/p>\n

Veiklas planuojama prad\u0117ti 2026 m. pirm\u0105j\u012f ketvirt\u012f, o gamybos etap\u0105 u\u017ebaigti iki met\u0173 pabaigos.<\/p>\n

Lietuvoje gaminamas vakcina gali tapti esminiu l\u016b\u017eiu suvaldant galimas pandemijos gr\u0117smes ateityje. <\/p>\n

Ketvirtadien\u012f \u201eNorthway Biotech\u201c informavo, kad taip pat prisijung\u0117 prie Lietuvos mokslo ir verslo konsorciumo bendradarbiavimui su Masa\u010dusetso technologijos institutu (MIT, JAV). Kaip pa\u017eymi bendrov\u0117, tai rei\u0161kia nauj\u0105 tarptautin\u012f gyvyb\u0117s moksl\u0173 bendradarbiavimo etap\u0105 \u2013 pramonin\u0117 biologini\u0173 vaist\u0173 k\u016brimo patirtis pirm\u0105 kart\u0105 sistemingai jungiama su lyderiaujan\u010dio pasaulyje MIT ir Lietuvos akademine kompetencija.<\/p>\n","protected":false},"excerpt":{"rendered":"Prane\u0161ime \u017einiasklaidai ra\u0161oma, kad \u201eExpreS2ion\u201c pasirinko \u201eNorthway Biotech\u201c kaip gamybos partner\u012f \u012fvertinusi s\u0117kming\u0105 ankstesnio bendradarbiavimo patirt\u012f ir \u012fmon\u0117s…\n","protected":false},"author":2,"featured_media":94899,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[19314,25,30,31,34,35,24,32,33,37,39,36,38,40,23,22,19290,44,28,29,26,27,3817,74,75,76],"class_list":{"0":"post-94898","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-pasaulis","8":"tag-northway","9":"tag-antrastes","10":"tag-breaking-news","11":"tag-breakingnews","12":"tag-featured-news","13":"tag-featurednews","14":"tag-headlines","15":"tag-latest-news","16":"tag-latestnews","17":"tag-lietuva","18":"tag-lietuviu","19":"tag-lithuania","20":"tag-lithuanian","21":"tag-lt","22":"tag-naujienos","23":"tag-news","24":"tag-nipos-virusas","25":"tag-pasaulis","26":"tag-populiariausios-naujienos","27":"tag-populiariausiosnaujienos","28":"tag-top-stories","29":"tag-topstories","30":"tag-vakcinos","31":"tag-world","32":"tag-world-news","33":"tag-worldnews"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@lt\/115982087148693074","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/94898","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/comments?post=94898"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/posts\/94898\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media\/94899"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/media?parent=94898"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/categories?post=94898"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/lt\/wp-json\/wp\/v2\/tags?post=94898"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}